Abstract
Several studies have shown promising results regarding the use of statins as an adjunctive treatment for sepsis. Most of those studies were retrospective or observational in nature. The ASEPSIS trial has reported that the administration of atorvastatin reduced clinical progression of sepsis but did not improve mortality. These findings are promising and further multicenter trials are needed to confirm these outcomes and to establish whether this class of medications will offer utility in this regard.
Highlights
In the previous issue of Critical Care, Patel and colleagues report the result of a single-center study that randomized septic patients to atorvastatin or placebo
The authors found that patients treated with statins had less transition to severe sepsis mortality was no different between the treated and untreated patients [1]
Main text The primaum mauvens in severe sepsis is thought to be an uncontrolled proinflammatory response triggered by infectious agents that leads to organ dysfunction
Summary
In the previous issue of Critical Care, Patel and colleagues report the result of a single-center study that randomized septic patients to atorvastatin or placebo. The authors found that patients treated with statins had less transition to severe sepsis mortality was no different between the treated and untreated patients [1]. These findings, promising, need to be confirmed in larger, multicenter trials. Severe sepsis is associated with high rates of morbidity and mortality. Sepsis is estimated to be directly responsible for more than 200,000 deaths and results in $17 billion of costs annually [2,3]. 30 to 40% of patients with severe sepsis still die in the ICU [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
